Literature DB >> 16842946

Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005.

Shu-Fang Teng1, Shou-Chien Wu, Chiareiy Liu, Jih-Heng Li, Chun-Sheng Chien.   

Abstract

One hundred and eighty-one 3,4-methylenedioxymethamphetamine (MDMA) containing tablets were sampled from confiscated drugs received by the Taiwan National Bureau of Controlled Drugs for testing from 2002 to February 2005. Sample tablets demonstrated various colors and logos. The appearances, contents of MDMA and other components in these tablets were analyzed in order to understand the characteristics and trends of MDMA use. Samples were analyzed using GC-MS methodology. Deuterated internal standards were used for drug quantification. The MDMA contents varied from 16 to 193 mg/tablet. 66-71% of the tablets seized each year contained only MDMA, and the content of MDMA in MDMA only tablets varied from 89 to 133 mg/tablet. There was a decreasing trend in MDMA content in these tablets over time. Other components commonly found besides MDMA included caffeine (18%), methamphetamine (7%), 3,4-methylenedioxyethylamphetamine (MDEA) (7%) and amphetamine (4%). 3,4-Methylenedioxyamphetamine (MDA), ketamine, ephedrine, diazepam, chlorzoxazone and nicotinamide were also detected. During the study period, the number of other drugs found as well as the combinations of different drugs detected in these tablets increased.

Entities:  

Year:  2006        PMID: 16842946     DOI: 10.1016/j.forsciint.2006.03.035

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  5 in total

1.  Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques.

Authors:  Rebecca D Crean; Sophia A Davis; Michael A Taffe
Journal:  Pharmacol Biochem Behav       Date:  2007-04-03       Impact factor: 3.533

2.  Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.

Authors:  T Montgomery; C Buon; S Eibauer; P J Guiry; A K Keenan; G J McBean
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

3.  Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Denise I Briggs; Dina M Francescutti; Catherine E Sykes; Mrudang M Shah; David M Thomas; Donald M Kuhn
Journal:  J Neurochem       Date:  2013-01-08       Impact factor: 5.372

4.  Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Nieves Herrera-Mundo; Dina M Francescutti; Donald M Kuhn
Journal:  Life Sci       Date:  2013-07-24       Impact factor: 5.037

5.  Methylone and monoamine transporters: correlation with toxicity.

Authors:  Chiharu Sogawa; Norio Sogawa; Kazumi Ohyama; Ruri Kikura-Hanajiri; Yukihiro Goda; Ichiro Sora; Shigeo Kitayama
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.